Ting-Ting Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ting-Ting Wang has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Hou-Sheng Deng
Department of Anesthesiology, Chenzhou NO.1 People's Hospital, Chenzhou, 423000, PR China
1 shared publication- Huadong Ni
Department of Anesthesiology and Pain Research Center, The Affiliated Hospital of Jiaxing University
1 shared publication Huan Pan
Department of Central Laboratory, The First Affiliated Hospital of Jiaxing University, Jiaxing, 314001, PR China
1 shared publication- Hui Shen
Department of Geriatrics, Fujian Institute of Geriatrics, Fujian Medical University Union Hospital , 29 Xinquan Road, Fuzhou , Fujian , 350001 , China
1 shared publication - Jianjun Zhu
Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article
1 shared publication - Lin-Lin Hu
Sleep Medicine Center, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China
1 shared publication
Latest Publications
- 1 January 2020
- Published by Elsevier in Neuroscience Letters
- Vol. 714, 134595
SAP102 contributes to hyperalgesia formation in the cancer induced bone pain rat model by anchoring NMDA receptors
- 1 January 2020
- Published by Elsevier in Neuroscience Letters
- Vol. 714, 134595
SAP102 contributes to hyperalgesia formation in the cancer induced bone pain rat model by anchoring NMDA receptors
- Open Access
- 1 January 2017
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2017 (1) , 8391637
Modified Suanzaorentang Had the Treatment Effect for Generalized Anxiety Disorder for the First 4 Weeks of Paroxetine Medication: A Pragmatic Randomized Controlled Study
Background. Paroxetine does not show satisfactory therapeutic effect for generalized anxiety disorder (GAD) patients for the first 2–4 weeks of medication. Diazepam is always concurrently used although it has some shortcomings such as physical dependence and withdrawal reactions. In this study, we aimed to identify whether modified Suanzaorentang (MSZRT), a combined Chinese formula including Suanzaorentang (SZRT) and Zhizichitang (ZZCT), could control the anxiety of GAD for the first 4 weeks of paroxetine medication. Methods. 156 GAD patients were randomized to the treatment of paroxetine, paroxetine‐diazepam, or paroxetine‐MSZRT for 4 weeks. Hamilton Anxiety Scale (HAMA) Test and Self‐Rating Anxiety Scale (SAS) Test were determined each week as the evaluation of clinical efficacy. Adverse events (AEs) were also closely observed by performing the Treatment Emergent Symptom Scale (TESS) Test. Results. Both paroxetine‐MSZRT and paroxetine‐diazepam decreased more HAMA and SAS total scores than paroxetine from weeks 1 to 3. Paroxetine‐MSZRT as well as paroxetine‐diazepam had an obviously higher onset rate than paroxetine in each week. After 4 weeks’ treatment, the overall effectiveness rate in the paroxetine‐MSZRT group (90.00%) was obviously higher than those of the paroxetine group (74.42%) but did not significantly differ from the paroxetine‐diazepam group (93.88%). Conclusion. MSZRT had the treatment effect for GAD when paroxetine was used for the first 4 weeks.
- 1 January 2017
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2017 (1) , 8391637
Open AccessModified Suanzaorentang Had the Treatment Effect for Generalized Anxiety Disorder for the First 4 Weeks of Paroxetine Medication: A Pragmatic Randomized Controlled Study
Background. Paroxetine does not show satisfactory therapeutic effect for generalized anxiety disorder (GAD) patients for the first 2–4 weeks of medication. Diazepam is always concurrently used although it has some shortcomings such as physical dependence and withdrawal reactions. In this study, we aimed to identify whether modified Suanzaorentang (MSZRT), a combined Chinese formula including Suanzaorentang (SZRT) and Zhizichitang (ZZCT), could control the anxiety of GAD for the first 4 weeks of paroxetine medication. Methods. 156 GAD patients were randomized to the treatment of paroxetine, paroxetine‐diazepam, or paroxetine‐MSZRT for 4 weeks. Hamilton Anxiety Scale (HAMA) Test and Self‐Rating Anxiety Scale (SAS) Test were determined each week as the evaluation of clinical efficacy. Adverse events (AEs) were also closely observed by performing the Treatment Emergent Symptom Scale (TESS) Test. Results. Both paroxetine‐MSZRT and paroxetine‐diazepam decreased more HAMA and SAS total scores than paroxetine from weeks 1 to 3. Paroxetine‐MSZRT as well as paroxetine‐diazepam had an obviously higher onset rate than paroxetine in each week. After 4 weeks’ treatment, the overall effectiveness rate in the paroxetine‐MSZRT group (90.00%) was obviously higher than those of the paroxetine group (74.42%) but did not significantly differ from the paroxetine‐diazepam group (93.88%). Conclusion. MSZRT had the treatment effect for GAD when paroxetine was used for the first 4 weeks.